Among the CCR5 inhibitors developed so far, maraviroc is the first drug that has been approved by the US FDA for treating patients with R5 HIV-1. Although many CXCR4 inhibitors, some of which are ...

This possibility is especially promising because CXCR4 has been well studied in the context of HIV, where it is known to be a portal for the virus's entry into immune system cells. Drugs that ...

The Food and Drug Administration has approved a Boston ... In most patients, WHIM syndrome is caused by mutations in the CXCR4 gene. The FDA approval was based on the results of a late-stage ...

Under drug therapy, consequent switches back and forth between both coreceptors may also occur. The occurrence of CXCR4-using HIV-1 variants is generally indicative of an advanced stage of ...